TY - JOUR
T1 - Hepatitis C Virus–Associated Non-Hodgkin Lymphomas
T2 - Biology, Epidemiology, and Treatment
AU - Pozzato, Gabriele
AU - Mazzaro, Cesare
AU - Gattei, Valter
PY - 2017/8/1
Y1 - 2017/8/1
N2 - Eradication of hepatitis C virus (HCV) in indolent non-Hodgkin lymphomas (NHLs), especially in marginal zone lymphomas, determines the regression of the hematologic disorder in a significant fraction of cases. Because direct antiviral agents show an excellent profile in terms of efficacy, safety, and rapid onset of action, these drugs can be used in any clinical situation and in the presence of any comorbidities. To avoid the progression of the NHL, despite HCV eradication, antiviral therapy should be provided as soon as the viral infection is discovered; before that, the chronic antigenic stimulation determines the irreversible proliferation of neoplastic B cells.
AB - Eradication of hepatitis C virus (HCV) in indolent non-Hodgkin lymphomas (NHLs), especially in marginal zone lymphomas, determines the regression of the hematologic disorder in a significant fraction of cases. Because direct antiviral agents show an excellent profile in terms of efficacy, safety, and rapid onset of action, these drugs can be used in any clinical situation and in the presence of any comorbidities. To avoid the progression of the NHL, despite HCV eradication, antiviral therapy should be provided as soon as the viral infection is discovered; before that, the chronic antigenic stimulation determines the irreversible proliferation of neoplastic B cells.
KW - Direct antiviral agents
KW - Hepatitis C virus
KW - Marginal zone lymphoma
KW - Non-Hodgkin lymphoma
UR - http://www.scopus.com/inward/record.url?scp=85019374500&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85019374500&partnerID=8YFLogxK
U2 - 10.1016/j.cld.2017.03.006
DO - 10.1016/j.cld.2017.03.006
M3 - Review article
AN - SCOPUS:85019374500
SN - 1089-3261
VL - 21
SP - 499
EP - 515
JO - Clinics in Liver Disease
JF - Clinics in Liver Disease
IS - 3
ER -